0001192482-13-000246.txt : 20131219 0001192482-13-000246.hdr.sgml : 20131219 20131219142923 ACCESSION NUMBER: 0001192482-13-000246 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131217 FILED AS OF DATE: 20131219 DATE AS OF CHANGE: 20131219 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TETRALOGIC PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001361248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 343 PHOENIXVILLE PIKE CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 610-889-9900 MAIL ADDRESS: STREET 1: 343 PHOENIXVILLE PIKE CITY: MALVERN STATE: PA ZIP: 19355 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Woody James N. CENTRAL INDEX KEY: 0001553355 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36208 FILM NUMBER: 131288058 MAIL ADDRESS: STREET 1: C/O ONCOMED PHARMACEUTICALS, INC. STREET 2: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2013-12-17 0001361248 TETRALOGIC PHARMACEUTICALS CORP TLOG 0001553355 Woody James N. C/O TETRALOGIC PHARMACEUTICALS CORP 343 PHOENIXVILLE PIKE MALVERN PA 19355 1 0 0 0 Common Stock 2013-12-17 4 P 0 243189 7.00 A 243189 I See footnotes Common Stock 2013-12-17 4 P 0 12159 7.00 A 255348 I See footnotes Common Stock 2013-12-17 4 P 0 6079 7.00 A 261427 I See footnotes Common Stock 2013-12-17 4 C 0 354663 A 616090 I See footnotes Common Stock 2013-12-17 4 C 0 17733 A 633823 I See footnotes Common Stock 2013-12-17 4 C 0 8866 A 642689 I See footnotes Common Stock 2013-12-17 4 C 0 227266 A 869955 I See footnotes Common Stock 2013-12-17 4 C 0 11363 A 881318 I See footnotes Common Stock 2013-12-17 4 C 0 5681 A 886999 I See footnotes Common Stock 2013-12-17 4 C 0 104118 7.00 A 991117 I See footnotes Common Stock 2013-12-17 4 C 0 5205 7.00 A 996322 I See footnotes Common Stock 2013-12-17 4 C 0 2602 7.00 A 998924 I See footnotes Common Stock 2013-12-17 4 X 0 2850 6.4022 A 1001774 I See footnotes Common Stock 2013-12-17 4 X 0 143 6.4022 A 1001917 I See footnotes Common Stock 2013-12-17 4 X 0 71 6.4022 A 1001988 I See footnotes Series B Convertible Preferred Stock 2013-12-17 4 C 0 354663 D Common Stock 354663 0 I See footnotes Series B Convertible Preferred Stock 2013-12-17 4 C 0 17733 D Common Stock 17733 0 I See footnotes Series B Convertible Preferred Stock 2013-12-17 4 C 0 8866 D Common Stock 8866 0 I See footnotes Series C Convertible Preferred Stock 2013-12-17 4 C 0 227266 D Common Stock 227266 0 I See footnotes Series C Convertible Preferred Stock 2013-12-17 4 C 0 11363 D Common Stock 11363 0 I See footnotes Series C Convertible Preferred Stock 2013-12-17 4 C 0 5681 D Common Stock 5681 0 I See footnotes Convertible Notes 7.00 2013-12-17 4 C 0 104118 D Common Stock 104118 0 I See footnotes Convertible Notes 7.00 2013-12-17 4 C 0 5205 D Common Stock 5205 0 I See footnotes Convertible Notes 7.00 2013-12-17 4 C 0 2602 D Common Stock 2602 0 I See footnotes Series C Warrants 6.4022 2013-12-17 4 X 0 2850 D Common Stock 2850 0 I See footnotes Series C Warrants 6.4022 2013-12-17 4 X 0 143 D Common Stock 143 0 I See footnotes Series C Warrants 6.4022 2013-12-17 4 X 0 71 D Common Stock 71 0 I See footnotes Directly owned by LVP Life Science Ventures, III, L.P. Directly owned by LVP III Associates, L.P. Directly owned by LVP III Partners, L.P. Shares of Series B Convertible Preferred Stock were automatically converted to the same number of shares of Common Stock at the time of the Company's initial public offering on December 17, 2013. Shares of Series C Convertible Preferred Stock were automatically converted to the same number of shares of Common Stock at the time of the Company's initial public offering which occurred on December 17, 2013. The Convertible Notes and Accrued Interest automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering, at the initial public offering price of $7.00 per share, which occurred on December 17, 2013. The warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for a number of shares of common stock equal to the warrant amount divided by $6.4022 and net exercised at the initial public offering price of $7.00 per share. The reported securities are owned directly by each of LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates"), and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates, and Partners. The reporting person, a member of GP III, shares voting and investment power with respect to these shares but disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein /s/ Richard L. Sherman, Attorney-In-Fact for James N. Woody 2013-12-19